Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name MediLink Therapeutics (Suzhou) Co., Ltd. appears in 13 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials13
Recruiting shown11
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

13 shown
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung CancerNCT07739758 · lead sponsor · 2026-08-18
RECRUITING
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid TumorsNCT07407933 · lead sponsor · 2026-03-31
RECRUITING
Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerNCT07416994 · lead sponsor · 2026-03-18
RECRUITING
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerNCT07461454 · lead sponsor · 2026-03-17
RECRUITING
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid TumorsNCT07208773 · lead sponsor · 2025-10-29
RECRUITING
A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsNCT07169994 · lead sponsor · 2025-09-02
RECRUITING
A Study of YL202 in Patients With Advanced Solid TumorsNCT07202364 · lead sponsor · 2025-08-04
RECRUITING
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCNCT06439771 · lead sponsor · 2024-04-23
RECRUITING
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPCNCT06241846 · lead sponsor · 2024-02-22
RECRUITING
A Study of YL202 in Selected Patients With Advanced Solid TumorsNCT06107686 · lead sponsor · 2023-12-15
RECRUITING
A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)NCT06612151 · lead sponsor · 2024-12-17
ACTIVE_NOT_RECRUITING
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast CancerNCT05653752 · lead sponsor · 2022-12-20
ACTIVE_NOT_RECRUITING
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)NCT07111520 · collaborator · 2025-09-22
RECRUITING

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing MediLink Therapeutics (Suzhou) Co., Ltd. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
atezolizumab1
capecitabine1
carboplatin1
docetaxel1
eribulin1
etoposide1
gemcitabine1
sacituzumab govitecan1

Sponsor roles

lead sponsor12
collaborator1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.